Joseph C. Papa
CEO, President & DirectorMr. Joseph C. Papa, Jr. also known as Joe, R.Ph., M.B.A., is Independent Non-Executive Director of Milestone Pharmaceuticals Inc. since September 3, 2024. Mr. Papa serves as Executive Advisor at Water Street Healthcare Partners, LLC since joining in June 13, 2023. He serves as Chairman at SparingVision SAS since March 2023. He served as Chief Executive Officer at Bausch + Lomb Corporation since January 2022 until March 6, 2023 and served as its Chairman of the Board since January 2022 until July 2022. He serves as Independent Director at Candel Therapeutics, Inc. since August 08, 2022. He serves as Chief Executive Officer and President at Emergent BioSolutions Inc. since February 21, 2024 and serves as its Director since 2024. He is Non-Executive Director of Smith & Nephew Orthopaedics Ltd from August 2008. He joined the Smith & Nephew Orthopaedics Ltd in August 2008. He was Chairman of Perrigo and Chief Executive Officer of Perrigo of PBM Products, LLC. He is Chair & Chief Executive Officer of Valeant Pharmaceuticals International, Inc. He joined the Valeant Pharmaceuticals International, Inc. in May 2016. He serves as Director at Bausch + Lomb Corporation since January 2022. He served as an Independent Director of Prometheus Biosciences, Inc since August 2020 until June 16, 2023 and served as its Lead Independent Director since August 2021 until June 16, 2023. He served as the Chairman of the Board of Bausch Health Companies Inc. since May 2, 2016 until June 2022 and served as Chief Executive Officer since May 2, 2016 until 2022. He served as Independent Director at Bausch Health Companies Inc. until June 2022. Mr. Papa served as the Chief Executive Officer of Perrigo Company plc since October 9, 2006 to April 24, 2016 and served as its Chairman from October 31, 2007 to April 24, 2016. Mr. Papa serves as Chairman and Chief Executive Officer of Wrafton Laboratories Ltd. He served as the President of Perrigo Company of Tennessee Inc. He served as the Chairman and Chief Executive Officer of Perrigo Company of South Carolina, Inc. He served as the President of SPC Trademarks, LLC. He served as the President of Perrigo Company plc from October 2006 to October 22, 2015. He served as the Chairman and Chief Executive Officer of Pharmaceutical Technologies & Services Business of Cardinal Health, Inc. from December 2004 to October 2006. He served as the President of Actavis, Inc. from October 2002 to November 19, 2004 and served as its Chief Operating Officer from November 2001 to November 19, 2004. Prior to joining Actavis, Inc. he served as the President and Chief Operating Officer of DuPont Pharmaceuticals Company from February 2001 to November 2001. He served as the President of Allergan plc from October 2002 to November 2014 and served as its Chief Operating Officer from November 2001 to November 2004. From September 1997 to April 2000, Mr. Papa served as the President of US Operations of Searle Pharmaceuticals Company. In 1999, he led the team that launched the arthritis pain medication Celebrex in the US, widely regarded as the most successful new therapy launch at the time. He held management positions at G.D. Searle & Company, Novartis AG, Novartis Pharmaceuticals Corp. Ciba Geigy Pharmaceuticals and Geneva Pharmaceuticals. He began his career as a pharmacist. From 2001 to 2004, he served as President and Chief Operating Officer of Watson Pharmaceuticals, Inc. (Watson). He served as a Consulting Intern in the health care group of Ernst & Whinney. He served as an Independent Non-Executive Director of Smith & Nephew plc since August 1, 2008 until April 12, 2018 and has been an Independent Non-Executive Director of Smith & Nephew, Inc. since August 1, 2008. Prior to joining Watson, Mr. Papa has also held management positions at Pharmacia/Searle. His track record for leadership continued as he served as President and Chief Operating Officer for Watson Pharmaceuticals (2001-2004), President of Global Country Operations for Pharmacias North American business (2000-2001) and President of Searles US Operations (1997-2000). During his career at Novartis Pharmaceuticals, he and his teams successfully launched the pharmaceutical products Lotrel, Divovan and Celebrex. Mr. Papa serves on the Board of Prometheus Biosciences and had been a previous member of the Boards for the UConn Foundation and Smith & Nephew. Mr. Papa served as a Director of Perrigo Company plc from November 10, 2006 to April 24, 2016. Papa held the role of President and Chief Operating Officer at Watson Pharmaceuticals and worked at Novartis Pharmaceuticals in the U.S. and Switzerland. Mr. Papa has a Bachelor of Science degree in Pharmacy from the University of Connecticut in 1978 and Master of Business Administration degree in Marketing and Finance from Northwestern University's Kellogg Graduate School of Management in 1983. He received an Honorary Doctor of Science degree from the University of Connecticut School of Pharmacy in 2012.
Positions
- Company NameEmergent BioSolutions Inc.Stock CodeEBSPositionCEO, President & DirectorColleagues
- ZPZsolt P. HarsanyiIndependent Non-Executive Chairman
- RSRichard S. LindahlExecutive VP, CFO and Principal Financial & Accounting Officer
- CGColeen GlessnerExecutive Vice President of Quality, Ethics & Compliance
- PAPaul A. WilliamsSenior Vice President of Products Business
- JPJessica PerlSenior VP, Corporate Secretary & General Counsel
- MLMarvin L. WhiteIndependent Director
- STSujata T. DayalIndependent Director
- DWDonald W. DeGolyerIndependent Director
